Is fostatinib/fotantinib already on the market in the country?

Fostamatinib, an oral small molecule drug targeting SYK, has been approved in many countries around the world for the treatment of patients with chronic immune thrombocytopenia (ITP), but it has not yet been officially launched in the Chinese market. The original drug has not yet been approved by the domestic drug registration system, so it cannot be purchased through hospitals or pharmacies, and it is not covered by medical insurance. If domestic patients want to use fostatinib, they currently mainly rely on overseas channels or participation in international clinical trials to obtain the drug, which has certain limitations in terms of accessibility and cost.

In overseas markets, the common specifications of fostatinib are 100 mg × 60 tablets and 150 mg × 60 tablets. Oral administration facilitates long-term management of platelet levels by patients in a home environment. Although the original version has not yet entered the domestic market, domestic pharmaceutical companies have begun to pay attention to the clinical application potential of fostatinib. In the future, it may enter the country in the form of generic drugs or innovative drugs to meet the treatment needs of domestic ITP patients.

It should be pointed out that the medication management of fostatinib must follow the guidance of a doctor, including dosage adjustment and regular monitoring of hematology and liver function indicators to ensure safety. Its pre-market availability is limited, and domestic patients are reminded to strictly screen channels when using overseas drugs to avoid the risk of counterfeit or substandard drugs. With the accumulation of clinical data and the advancement of domestic drug approval processes, the launch of fostatinib in China is expected to provide new oral targeted treatment options for patients with refractoryITP, and is also expected to promote the modernization and personalized process of domestic blood immune disease management.

In general, fostatinib has not yet been marketed in China, but its clear targeting mechanism, oral convenience and potential efficacy in refractory ITP make it an important candidate drug for domestic hematology treatment in the future.

Reference materials:https://go.drugbank.com/drugs/DB12010